U.S. Banks Stock News

Hain Celestial Group (HAIN) has just posted Q2 2026 numbers that keep the focus firmly on profitability, with Q1 2026 revenue at US$367.9 million and a basic EPS loss of US$0.23 setting the tone for the latest update. Over recent quarters, the company has seen revenue move from US$418.8 million in Q4 2024 to US$411.5 million in Q2 2025 and US$367.9 million in Q1 2026, while basic EPS shifted from a loss of US$0.03 in Q4 2024 to a much wider loss of US$3.06 in Q4 2025 before narrowing again to...

Amentum Holdings reported first-quarter 2026 earnings with sales of US$3,237 million versus US$3,416 million a year earlier, while net income rose to US$44 million from US$12 million, lifting earnings per share from continuing operations to US$0.18 from US$0.05. Alongside these results, Amentum’s role in Deep Isolation’s deep borehole nuclear waste demonstration and up to US$730 million in new EDF nuclear contracts underline its expanding footprint across both nuclear operations and...

Outdoor Holding (POWW) has released its Q3 2026 scorecard, reporting recent quarterly revenue of about US$12.0 million in Q2 2026 and basic EPS of roughly US$0.006, following a loss per share of US$0.057 in Q1 2026. The company’s revenue has moved from US$34.5 million in Q3 2024 to US$28.0 million in Q3 2025 and then to US$12.0 million in Q2 2026. Over the same period, basic EPS has shifted from a loss of US$0.027 per share in Q3 2024 to a loss of US$0.232 in Q3 2025, before landing just...

If you are wondering whether NIO at about US$4.89 is a bargain or a value trap, you are not alone. This breakdown is here to unpack that question in more detail. The share price has moved 8.2% over the last week and 5.4% over the last 30 days, while the year to date return is a 4.9% decline and the 1 year return sits at 12.9%. This compares with much weaker 3 year and 5 year returns of 52.6% and 91.8% declines respectively. Recent coverage of NIO has focused on its position in the electric...

Why Klarna Group is on investors’ radar Klarna Group (KLAR) has drawn attention after recent trading, with the share price at US$20.37 and short term returns under pressure over the past week, month, and past 3 months. See our latest analysis for Klarna Group. For context, Klarna Group’s recent weakness has been building for a while, with a 1-day share price return of 0.73% decline, a 30-day share price return of 35.23% decline, and a year to date share price return of 28.70% decline. This...

If you are wondering whether Jumia Technologies is still attractively priced after its recent volatility, you are not alone. This article will walk through what the current market price might be implying. The stock last closed at US$12.27, with returns of 195.7% over 1 year and 225.5% over 3 years, alongside shorter term moves of a 0.7% decline over 7 days, a 14.0% decline over 30 days, and a 4.4% decline year to date. These mixed returns, strong over several years but weaker in the near...

PowerFleet (AIOT) has just posted its latest numbers, with Q2 2026 revenue at US$111.7 million and a basic EPS loss of US$0.03, setting the stage for how you read the new Q3 2026 update. Over recent periods the company has seen revenue move from US$75.4 million and an EPS loss of US$0.21 in Q1 2025 to US$106.4 million with an EPS loss of US$0.11 in Q3 2025, then to US$103.6 million and an EPS loss of US$0.09 in Q4 2025, and US$104.1 million with an EPS loss of US$0.08 in Q1 2026. With the...

Why Maze Therapeutics (MAZE) Is On Investors’ Radar Maze Therapeutics (MAZE) has drawn fresh attention after recent trading, with the stock closing at $47.71 and showing strong trailing returns over the past year. This performance has prompted investors to reassess its clinical stage profile. See our latest analysis for Maze Therapeutics. The recent 5.95% 1 day share price return, on top of a 47.89% 90 day share price return and a very large 1 year total shareholder return of about 7x,...

Motorcar Parts of America (MPAA) has put out its latest quarterly scorecard, with Q2 2026 revenue at US$221.47 million and basic EPS of a US$0.11 loss, alongside trailing twelve month revenue of US$789.12 million and basic EPS of US$0.13. Over the past few reported periods, the company has seen revenue move from US$169.89 million in Q1 2025 to US$208.19 million in Q2 2025, US$186.18 million in Q3 2025, US$193.11 million in Q4 2025, US$188.36 million in Q1 2026, and US$221.47 million in Q2...

Venture Global overview after recent price moves Venture Global (VG) has drawn attention after a recent share price move, with the stock closing at US$10.17 and showing mixed return patterns across the past week, month and past 3 months. See our latest analysis for Venture Global. Recent moves sit on top of a much bumpier year, with a year to date share price return of 44.46% and a 1 year total shareholder return decline of 40.50%, suggesting recent momentum has not yet fully repaired earlier...

Hexcel’s recent performance and what it could mean for investors Hexcel (HXL) has attracted fresh attention after a strong past 3 months, with the stock showing a 25.03% total return and a 32.49% total return over the past year. See our latest analysis for Hexcel. At a share price of $86.06, Hexcel’s recent 7 day and 90 day share price returns of 5.48% and 25.03% sit alongside a 32.49% 1 year total shareholder return. This suggests momentum has been building rather than fading. If Hexcel’s...

IQVIA Holdings reported fourth-quarter 2025 sales of US$4,364 million and full-year sales of US$16,310 million, alongside issuing 2026 revenue guidance of US$17,150 million to US$17,350 million that factors in acquisition and foreign-exchange benefits. Recent moves, including a long-term Data-as-a-Service collaboration with Boehringer Ingelheim and ongoing share repurchases under a multi-year program, underline IQVIA’s push to deepen its role in data-driven healthcare decision-making. We’ll...

EQT Corporation's Board of Directors has declared a quarterly cash dividend. The dividend decision reflects the company's ongoing commitment to returning cash to shareholders. The announcement arrives as EQT (NYSE:EQT) trades around $56.13 per share. EQT, trading at about $56.13, has attracted attention with multi year returns that are very large, including a 90.5% return over 3 years and a 238.3% return over 5 years. In the shorter term, the stock shows a 9.9% return over the past 30 days...

For investors wondering whether Intel at US$50.24 is still reasonably priced or if most of the easy gains are already behind it, this article walks through what the current numbers are really saying about the stock. Over the short term, Intel has returned 2.9% over the last 7 days and 10.3% over the last 30 days. Its year to date return is 27.6% and its 1-year return is 154.1%, compared to 80.3% over 3 years and a 10.6% decline over 5 years. These mixed return figures sit against a backdrop...

Sohu.com (SOHU) just posted its FY 2025 third quarter numbers, with revenue of US$180.2 million, basic EPS of US$0.32 and net income excluding extra items of US$8.7 million setting the tone for the latest update. The company has seen revenue move from US$151.9 million in Q3 2024 to US$180.2 million in Q3 2025, while basic EPS shifted from a loss of US$0.52 to a profit of US$0.32. This gives investors a cleaner read on how margins are shaping up after a volatile run of results. See our full...

Cleveland Cliffs (CLF) just posted its FY 2025 numbers with Q3 revenue of US$4.7b and a basic EPS loss of US$0.50, alongside trailing twelve month revenue of US$18.6b and a basic EPS loss of US$3.40. Over recent quarters the company has seen revenue move between US$4.3b and US$5.2b while basic EPS has ranged from a small loss of roughly US$0.00 to a loss of US$1.00 per quarter, setting a mixed backdrop for how you read this latest print. With the shares at US$12.31, investors are likely to...

Dynatrace (DT) just posted its Q3 2026 scorecard with recent quarterly revenue running at about $493.8 million and Basic EPS of roughly $0.19, set against a trailing 12 month picture that includes Basic EPS of $1.69 and revenue of about $1.9 billion, plus earnings growth in the dataset of 210.1% over the past year. The company has seen revenue move from $399.2 million in Q1 2025 to $493.8 million in Q2 2026 and quarterly Basic EPS shift from $0.13 to $0.19 over the same period. Year long...

Waters (WAT) FY 2025 earnings snapshot Waters (WAT) reported Q3 FY 2025 revenue of US$799.9 million and basic EPS of US$2.50, with trailing 12 month EPS of US$10.91 on revenue of about US$3.1 billion. The company’s quarterly revenue rose from US$708.5 million in Q2 2024 to US$771.3 million in Q2 2025, and then to US$799.9 million in Q3 2025. Over the same periods, basic EPS moved from US$2.41 to US$2.47 and then to US$2.50, highlighting a story focused on consistent earnings and resilient...

Why Brookfield Business Partners Stock Is Back on Investors’ Radar Brookfield Business Partners (NYSE:BBU) just paired its 2025 earnings release with a fresh share buyback update and an affirmed dividend plan tied to its upcoming corporate reorganization, drawing fresh attention from income focused investors. See our latest analysis for Brookfield Business Partners. The confirmed dividend, completed 1% share buyback and narrowing annual net loss have arrived alongside stronger trading...

Roblox (NYSE:RBLX) reported strong fourth quarter results, highlighting solid bookings and active user metrics. The company introduced facial age estimation and more than 145 new safety initiatives across its platform. Management emphasized a focus on leading online safety standards for both younger users and a growing adult audience. Roblox runs a global 3D social and gaming platform where users create, share, and play content built by the community. The latest safety updates sit alongside...

In early February 2026, Exact Sciences reported that its Oncotype DX Breast Recurrence Score test has now guided treatment decisions for more than two million early-stage HR+, HER2- breast cancer patients worldwide, supported by over two decades of clinical evidence and broad global adoption. The company highlighted that Oncotype DX remains the only genomic assay proven to be both prognostic and predictive for chemotherapy benefit, with published models suggesting meaningful lifetime cost...

Meritage Homes (MTH) is back in focus after its latest earnings release, which combined lower annual revenue and net income with real estate impairments, flat 2026 revenue guidance, sizable buybacks, and record community growth. See our latest analysis for Meritage Homes. At a share price of $75.91, Meritage Homes has seen stronger recent momentum, with a 7 day share price return of 8.15% and a 90 day share price return of 10.21%. Its 5 year total shareholder return of 83.21% shows how the...

Recent research coverage highlights Excelerate Energy’s history of outperforming earnings estimates, pointing to past quarterly surprises and a current positive Earnings ESP, with the next report scheduled for February 25, 2026. An interesting angle is how the combination of a positive Earnings ESP and a mid-range Zacks Rank is shaping expectations around Excelerate Energy’s ability to outpace consensus forecasts. With this backdrop of anticipated earnings outperformance, we’ll explore what...

Denali Therapeutics (DNLI) has drawn fresh attention after presenting clinical and preclinical data at the 22nd Annual WORLDSymposium, updating investors on its Enzyme Transport Vehicle programs and upcoming regulatory milestones for rare disease candidates. See our latest analysis for Denali Therapeutics. Those WORLDSymposium updates and the recent shareholder and analyst call come after a 90 day share price return of 35.13% and a 30 day share price return of 23.42%. However, the 1 year...